Fighting cancer with precision and power.
Bicara Therapeutics is a clinical-stage biotechnology company developing first-in-class bifunctional biologics that combine tumor-targeting antibodies with tumor microenvironment modulators to treat solid tumors. Its bifunctional antibody platform is designed to deliver immunomodulatory payloads directly to the tumor site, enabling synergistic anti-tumor immune activity. The company is publicly traded (Nasdaq: BCAX) and advancing its lead programs through Phase 1b and Phase 3 clinical trials.
Create a free account to see funding visualizations and detailed round data.
Create Free AccountCreate a free account to see full funding history, valuations, and investor participation.
Create Free AccountCreate a free account to see which investors have funded this company.
Create Free Account